EGFR and Thromboembolism: Similarly, in the multivariate analysis of Model 1 and Model 2, the use of VEGF and EGFR inhibitors was not identified as a risk factor, whereas having at least one risk factor for thromboembolism was identified as a risk factor (P = 0.006, P = 0.006, respectively; Table 3).